Application | Comment | Organism |
---|---|---|
medicine | target for suppression of estrogen synthesis in breast cancer | Homo sapiens |
Crystallization (Comment) | Organism |
---|---|
hanging drop vapor diffusion method | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
EM-1745 | strong competitive inhibitor, inhibition reversible, 50% inhibition at 52 nM | Homo sapiens |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
estrone + NADPH + H+ | Homo sapiens | final step in the synthesis of active estrogens | estradiol-17beta + NADP+ | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P14061 | isotype 1, 17beta-HSD type 1 | - |
Purification (Comment) | Organism |
---|---|
- |
Homo sapiens |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
placenta | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
5-androstene-3beta-ol-17-one + NADPH | - |
Homo sapiens | 5-androstene-3beta,17beta-diol + NADP+ | - |
? | |
estrone + NADPH + H+ | - |
Homo sapiens | estradiol-17beta + NADP+ | - |
? | |
estrone + NADPH + H+ | final step in the synthesis of active estrogens | Homo sapiens | estradiol-17beta + NADP+ | - |
? |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
NADPH | - |
Homo sapiens |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.000003 | - |
EM-1745 | pH 7.5, 37°C | Homo sapiens |